Renal Cell Carcinoma

The FDA granted fast track designation to ALLO-316, an investigational chimeric antigen receptor T-cell therapy, for the treatment of adults with advanced or metastatic clear cell renal cell carcinoma.

SAN FRANCISCO — Certain immune cell-related parameters appeared associated with efficacy of immune checkpoint inhibitors among patients with advanced or metastatic clear cell renal cell carcinoma, according to study results.

SAN FRANCISCO — Axitinib combined with nivolumab demonstrated encouraging efficacy among treatment-naive patients with metastatic renal cell carcinoma, according to study results presented at ASCO Genitourinary Cancers Symposium.

Sequential radiotherapy to defer systemic therapy appeared to be a feasible strategy with encouraging PFS and OS among select patients with oligometastatic renal cell carcinoma, according to a study published in The Lancet Oncology.

Cabozantinib demonstrated intracranial activity and appeared safe among patients with renal cell carcinoma and brain metastases, according to a study in JAMA Oncology.

Belzutifan demonstrated clinical efficacy among patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to results of a phase 2 study published in The New England Journal of Medicine.

The FDA expanded the approval of pembrolizumab to include adjuvant treatment of certain patients with renal cell carcinoma.

First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Tivozanib induced a significantly higher disease control rate than sorafenib among patients with relapsed or refractory advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.

Nivolumab plus cabozantinib improved outcomes compared with sunitinib regardless of prior nephrectomy among patients with advanced renal cell carcinoma, according to study results presented at International Kidney Cancer Symposium.